Vaccines work by inducing the human immune system to make antibodies that can neutralize a particular pathogen. But doing so for the Human Immunodeficiency Virus (HIV) has been challenging, says the U.S. National Institutes of Medicine (NIH).
More than a decade ago, researchers at the Vaccine Research Center of NIH's National Institute of Allergy and Infectious Diseases discovered a class of rare antibodies called broadly neutralizing antibodies (bnAbs) against HIV that could neutralize many HIV strains at once.
But inducing bnAbs with a vaccine has proven difficult.
Vaccines Could End the HIV Pandemic
Deaths Mentioning Long COVID Identified in United States
Percentage of COVID-19 deaths with long COVID peaked in June 2021 and April 2022 at 1.2 and 3.8 percent
Postop CV Morbidity Down With Increased Time From COVID-19 to Surgery
Odds of major postoperative cardiovascular morbidity reduced with increased time from COVID-19 diagnosis to surgery